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Background: To assess the biochemical recurrence (BCR)-free rate in patients who underwent prostate low-dose-rate
brachytherapy (LDR-brachytherapy), using two different definitions (Phoenix definition and PSA≥ 0.2 ng/mL).
Methods: Two hundreds and three patients who were clinically diagnosed with localized prostate cancer
(cT1c-2cN0M0) and underwent LDR-brachytherapy between July 2004 and September 2008 were enrolled. The
median follow-up period was 72 months. We evaluated the BCR-free rate using the Phoenix definition and the
PSA cut-off value of 0.2 ng/mL, as in the definition for radical prostatectomy. To evaluate an independent variable that
can predict BCR, Cox’s proportional hazard regression analysis was carried out.
Results: The BCR-free rate in patients using the Phoenix definition was acceptable (5-year: 92.8%). The 5- year BCR-free
rate using the strict definition (PSA≥ 0.2 ng/mL) was 74.1%. Cox’s proportional hazard regression analysis showed
that a higher biological effective dose (BED) of ≥180 Gy2 was the only independent variable that could predict BCR
(HR: 0.570, 95% C.I.: 0.327-0.994, p = 0.048). Patients with a higher BED (≥180 Gy2) had a significantly higher BCR-free
rate than those with a lower BED (<180 Gy2) (5-year BCR-free rate: 80.5% vs. 67.4%).
Conclusions: A higher BED ≥180 Gy2 promises a favorable BCR-free rate, even if the strict definition is adopted.
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Nowadays, low-dose-rate brachytherapy (LDR-brachy-
therapy) is one of the curative treatment options for
non-metastatic prostate cancer [1-6] alongside radical
prostatectomy and intensity modulated radiation therapy
(IMRT). Usually, the cut-off value in the definition of bio-
chemical recurrence is prostate specific antigen (PSA) of
0.2 ng/mL for patients who underwent radical prostatec-
tomy [7], and the Phoenix definition (nadir + 2 ng/mL) is
used for patients who underwent definitive radiation
therapy [8]. In several guidelines [9-11], the oncologic
outcome of radiation therapy is considered in the same
way as that of radical prostatectomy. However, it is in-
appropriate to compare the oncologic outcome between* Correspondence: sendo@naramed-u.ac.jp
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unless otherwise stated.surgery and radiation therapy using different definitions
(0.2 ng/mL vs. nadir + 2 ng/mL). From a radiation on-
cologist’s viewpoint, a cut-off value of 0.2 ng/mL is very
strict, because the prostate gland itself is still present
after radiation therapy. As long as different definitions are
used, direct comparison of oncologic outcome between sur-
gery and radiation therapy remains impossible. To address
this issue, we evaluated the oncologic outcome in patients
who underwent LDR-brachytherapy using both definitions
of biochemical recurrence (0.2 ng/mL vs. 2 ng/mL).Methods
Two hundreds and three patients who were clinically di-
agnosed with localized prostate cancer (cT1c-2cN0M0)
and underwent LDR-brachytherapy between July 2004
and September 2008 were enrolled in this study. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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dian age, PSA value at diagnosis, and follow-up period
were 70.0 years (range: 51–80), 7.4 ng/mL (range: 3.1-
32.1), and 72.0 months (range: 2–107), respectively. We
evaluated the biochemical recurrence-free rate using the
Phoenix definition. We also used the PSA cut-off value of
0.2 ng/mL to evaluate the biochemical recurrence-free
rate with the same definition as that used for radical
prostatectomy. If the PSA value after seed implantation
reached 0.2 ng/mL or more and showed a confirmatory
PSA of 0.2 ng/mL or higher, the patient was defined to
have biochemical recurrence the first time a PSA increase
was noted. If the PSA value did not fall to less than 0.2 ng/
mL, the patient was defined to have biochemical recurrence
at the date of seed implantation. A pathologist (K.N.), who
was expert in prostate cancer diagnosis, centrally reviewed
the Gleason score of all biopsy specimens. This study was
performed in compliance with the Helsinki Declaration.
The institutional review board approved this study, and
informed consent was obtained from all patients after
explaining the aim and methods of this study.Table 1 Patients’ characteristics stratified by biochemical









Median (range) 70.0 (51–80) 69.0 (55–79) 70.0 (51–80) 0.654§
PSA at diagnosis
(ng/mL)
Median (range) 7.4 (3.1-32.1) 7.2 (3.7-16.0) 7.4 (3.1-32.1) 0.834§
Biopsy gleason
score
6 or less 92 34 126
7 50 18 68
8-10 8 1 9 0.576*
Clinical T stage
T1c 95 29 124
T2a 44 20 64
T2b 8 2 10
T2c 3 2 5 0.563*
Neo-Adjuvant/
Adjuvant
None 104 37 141
Neo-Ad (+) 38 15 53
Ad (+) 4 1 5
Neo-Ad (+), Ad (+) 4 0 4 0.650*
EBRT
No 102 44 146
Yes 48 9 57 0.025*
*Chi-square test and §Mann–Whitney U test.Treatment
Of all 203 patients, 141 patients did not receive neoadju-
vant or adjuvant androgen deprivation therapy (ADT), 5
received adjuvant ADT, and 4 received both neoadjuvant
and adjuvant ADT. The remaining 53 received only neo-
adjuvant ADT. One hundred and forty-six underwent
only seed implantation and 57 patients received combin-
ation treatment including external beam radiation ther-
apy (Table 1).
Risk classification was according to D’Amico’s risk
classification [12]. The numbers of low-, intermediate-,
and high-risk patients were 93, 92, and 18 patients,
respectively (Table 2). Low-risk patients (cT2a, Gleason
score 6, and PSA ≤10 ng/mL) and patients (cT2a and
PSA ≤10 ng/mL) whose Gleason score of 3 + 4 with the
rate of positive biopsy core less than 50% were treated
by seed implantation alone. From July 2004 to April
2007, there were 95 patients who were treated with
seed implantation at a prescribed dose of 145 Gy, and
51 patients were treated at a prescribed dose of 160 Gy
after May 2007. The other patients received combination
treatment including external beam radiation therapy
(EBRT). The prescribed dose was 110 Gy. The target
portion of EBRT was determined one month after seed
implantation, and the patients received 45 Gy (in 25
fractions of 1.8 Gy per fraction) using 10 MV photon
energy. The clinical target volume included both the
whole prostate and one third of the proximal seminal
vesicle.
Of all patients, 64 patients were treated with a pre-
planning method and 139 with an intraoperative plan-
ning method by modified peripheral loading techniques
using Mick’s applicator [13].
Postdosimetric evaluation
The therapeutic planning and post-implant dosimetric
evaluation were performed using Interplant Version 3.3
(CMS, Inc., St. Louis, USA) planning system.
Post-implant CT scanning and post-implant dosimetric
studies were performed by one radiation oncologist (A.I.)
at 1 month after seed implantation. The dosimetric
parameters analyzed in this study were the minimal
percentage of the dose received by 90% of the prostate
gland (%D90), the percentage prostate volume receiving
100% of the prescribed minimal peripheral dose (V100),
and the biological effective dose (BED). BED was calcu-
lated to evaluate an independent factor that can predict
PSA bounce, and an α/β ratio of 2 was used [14].
Statistic analysis
The biochemical recurrence-free rate was estimated by
the Kaplan-Meier method. A log-rank test was used for
between-group comparison. The statistical difference
between the recurrence group and the non-recurrence









Low 65 28 93
Intermediate 70 22 92
High 15 3 18 0.400*
BED (Gy2)
Median (range) 183.8 (136.4-244.0) 171.8 (120.3-227.5) 180.6 (120.3-244.0) 0.009§
D90 (%)
Median (range) 110.6 (90.0-136.9) 108.6 (79.8-126.2) 110.3 (79.8-136.9) 0.106§
V100 (%)
Median (range) 94.5 (85.5-99.5) 93.9 (77.8-98.5) 94.3 (77.8-99.5) 0.124§
UD30 (%)
Median (range) 139.2 (99.4-200.3) 140.6 (104.2-197.9) 139.2 (99.4-200.3) 0.785§
R100 (mL)
Median (range) 0.01 (0.0-1.19) 0.04 (0.0-0.51) 0.02 (0.0-1.19) 0.207§
*Chi-square test and §Mann–Whitney U test, BED: biological effective dose.
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square test, while that for continuous variables was
tested by the Mann–Whitney U test. To evaluate an in-
dependent variable to predict biochemical recurrence,
Cox’s proportional hazard regression analysis was carried
out.
All statistical analyses were performed using PASW
Statistics 17.0 (SPSS Inc., Chicago, IL, USA). All p values
of less than 0.05 were considered statistically significant.
Results
Of all patients, 19 patients showed biochemical recur-
rence according to the Phoenix definition during the
follow-up period. The 5-year biochemical recurrence-



















Figure 1 The biochemical recurrence-free rate using the Phoenix
definition BCR: biochemical recurrence.recurrence-free rate in low, intermediate, and high-risk
patients was 93.5%, 91.8%, and 94.1%, respectively. There
was no significant difference between the different risk
groups (Figure 2). Regarding clinicopathological parame-
ters (e.g. PSA, Gleason score, age, clinical T stage, BED,
D90 (%), and V100), there were no significant differences
between patients who showed biochemical recurrence
and those who did not show recurrence.
On the other hand, 53 patients showed biochemical
recurrence during the follow-up period according to the
definition of PSA ≥0.2 ng/mL. The 5-year biochemical
recurrence-free rate was 74.1% (Figure 3). The 5-year
biochemical recurrence-free rate in the low, intermedi-


























Figure 2 The biochemical recurrence free rate stratified by
D’Amico risk classification using Phoenix definition BCR:
biochemical recurrence.



















Figure 3 The biochemical recurrence-free rate using the
definition of PSA ≥0.2 ng/mL BCR: biochemical recurrence.
Table 3 The number of patients and proportion stratified
by PSA value of the last follow-up
PSA (ng/mL) No of pts (%)
< 0.2 150 73.9
0.2 - 0.49 19 9.4
0.5 - 0.99 11 5.4
1.0 - 4 2.0
Nadir +2 19 9.4
Tanaka et al. Radiation Oncology 2014, 9:107 Page 4 of 6
http://www.ro-journal.com/content/9/1/107respectively. There was no significant difference between
the different risk groups (Figure 4). Among clinicopatho-
logical parameters, BED in the non-recurrence group was
significantly higher than that in the recurrence group (p =
0.009). In all 53 patients who showed biochemical recur-
rence according to the definition of PSA ≥0.2 ng/mL, 19
(35.8%) met the Phoenix definition, 4 (7.5%) had a PSA
value ≥ 1.0 ng/mL, 11 (20.8%) had a PSA value between
0.5 and 0.9 ng/mL, and 19 (35.8%) had a PSA value be-
tween 0.2 and 0.5 ng/mL, respectively (Table 3).
Cox’s proportional hazard regression analysis showed
that a higher BED of ≥180 Gy2 (median BED of all pa-
tients) was the only independent variable that could
predict biochemical recurrence after seed implantation
(HR: 0.570, 95% C.I.: 0.327-0.994, p = 0.048). Patients
with a higher BED (≥180 Gy2) had a significantly lower


























Figure 4 The biochemical recurrence free rate stratified by
D’Amico risk classification using PSA 0.2 ng/mL definition
BCR: biochemical recurrence.BED (<180 Gy2) (5-year biochemical recurrence-free rate:
80.5% vs. 68.4%, p = 0.025) (Figure 5).
Discussion
LDR-brachytherapy has been one of the definitive treat-
ment modalities for prostate cancer alongside radical
prostatectomy and IMRT, not only for low-risk patients
but also for intermediate and high-risk patients in recent
years [11]. The most recent report revealed that the bio-
chemical recurrence-free rate of patients who received
LDR-brachytherapy was similar to that of patients who
received radical prostatectomy [1-5]. The present study
also showed a favorable oncologic outcome according to
the Phoenix definition. However, using different defini-
tions to compare the oncologic outcome of radiation
therapy to that of radical prostatectomy is questionable.
To address this issue, Critz et al. reported the oncologic
outcome in patients who received LDR-brachytherapy in
combination with EBRT using the same definition for
biochemical recurrence as that for surgery [15]. They
concluded that the biochemical recurrence-free rate was




















5-year BCR-free rate 
67.4%
80.5%180 Gy2
BED < 180 Gy2
Figure 5 The biochemical recurrence-free rate stratified
by biologically effective dose (BED) using the definition of
PSA ≥ 0.2 ng/mL BCR: biochemical recurrence.
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recurrence-free rate was 74.1% with a median follow-up
period of 72 months. Most patients were classified as
low- or intermediate-risk in this cohort. This result gives
an unfavorable impression of seed implantation com-
pared to radical prostatectomy. On careful consider-
ation, however, the definition of PSA ≥0.2 ng/mL is very
strict for radiation therapy, because the prostate gland it-
self remains after radiation therapy, while the prostate
gland is essentially removed after radical prostatectomy.
The remaining prostate gland secretes subtle PSA after
radiation therapy. We also defined patients whose PSA
did not decrease to less than 0.2 ng/mL as biochemical
recurrence in this study. This definition is stricter than
that of the Critz study [15]. They defined an increase in
3 consecutive PSA measurements as biochemical recur-
rence in patients with a follow-up period of less than
5 years. Indeed, 19 patients (9.4%) in our study were de-
fined as biochemical recurrence, but the PSA value at
the last follow-up was between 0.2 and 0.49 ng/mL.
Taken together, 83.3% of patients showed a PSA value of
less than 0.5 ng/mL at the last follow-up (Table 3).
Interestingly, Cox’s proportional regression analysis
showed that BED was the only independent variable that
can predict biochemical recurrence in this study. We di-
vided all patients by using a 180 Gy2 cut-off value of
BED. This was the median value of BED for all patients.
The Kaplan-Meier curve showed a significant difference
in the 5-year biochemical recurrence-free rate (Figure 5:
80.5% vs. 67.4%, p = 0.025 by the log rank test). This
result indicated that a higher BED achieved a higher bio-
chemical recurrence-free rate using PSA ≥0.2 ng/mL
definition. Stone et al. also showed that BED was an
independent variable that can predict the cancer-free
rate of biopsy after seed implantation [16].
To compare the oncologic outcome in the same cat-
egory such as IMRT vs. brachytherapy, it is appropriate
to use the Phoenix definition. However, it is difficult to
compare the oncologic outcome between different mo-
dalities (e.g. surgery vs. radiation therapy) using different
definitions. Nielsen et al. reported that the biochemical
recurrence-free rate was overestimated by the Phoenix
definition compared to the standard definition (PSA
≥0.2 ng/mL) in patients who underwent radical prosta-
tectomy [17]. They insisted that the 5-year biochemical
control rates with a definition of 0.2 ng/mL or higher
should be compared with the 10-year biochemical con-
trol rates using the Phoenix definition.
In the present study, we demonstrated that most patients
(83.3%) achieved a PSA level of less than 0.5 ng/mL with
a median follow-up period of 72 months after seed im-
plantation. Patients who achieved a higher BED ≥180 Gy2
also showed a favorable biochemical recurrence-free rate
(80.5%) using the definition of PSA ≥ 0.2 ng/mL (Figure 5).We mostly treated the patients in the present study co-
hort by preplanned methods and the prescribed dose
was 145 Gy for monotherapy (95/146: monotherapy
pateints). We have now escalated the prescribed dose to
160 Gy and have adopted a real-time planning method.
The BED of current patients is at least 180 Gy2. We be-
lieve that the oncologic outcomes of the current patient
series will be more favorable than those in the present
study. We should compare the oncologic outcomes of
radical prostatectomy and LDR-brachytherapy using the
same definition.
The limitation of this study is the small number of pa-
tients. We did not discuss an inter-risk group compari-
son due to the small number of patients, especially in
the high-risk group (n = 18). Indeed, the oncologic out-
comes of high-risk group were not different compared
with other risk groups (low and intermediate) by either
definition. Longer follow-up periods will allow further
evaluation to make a definitive conclusion.
Conclusion
We reported the oncologic outcomes in Japanese pa-
tients who underwent LDR-brachytherapy with a median
follow-up period of 72 months using different definitions
of biochemical recurrence. Higher BED can promise a
favorable biochemical recurrence-free rate, even if a
strict definition is adopted.
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